Pathogenesis guided therapeutic management of COVID-19: an immunological perspective

References

• Worldometer. Coronavirus cases. Worldometer. 2020;1–22. https://www.worldometers.info/coronavirus/
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Muus C, Luecken MD, Eraslan G, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv. 2020. 2020.04.19.049254
   Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu S, Chen ZJ. SnapShot: pathways of antiviral innate immunity. Cell. 2010;140(3):436–436.e2. doi:10.1016/j.cell.2010.01.041.
   PubMed Web of Science ®Google Scholar
• Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc Natl Acad Sci USA. 2004;101(15):5598–5603. doi:10.1073/pnas.0400937101.
   PubMed Web of Science ®Google Scholar
• Kikkert M. Innate immune evasion by human respiratory RNA Viruses. J Innate Immun. 2020;12(1):4–20. doi:10.1159/000503030.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432. doi:10.1002/jmv.25685.
   PubMed Web of Science ®Google Scholar
• Broggi A, Ghosh S, Sposito B, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):eabc3545.
   Web of Science ®Google Scholar
• Lee HC, Chathuranga K, Lee JS. Intracellular sensing of viral genomes and viral evasion. Exp Mol Med. 2019;51(12):1–13. doi:10.1038/s12276-019-0299-y.
   Web of Science ®Google Scholar
• Cavaillon JM. Pro-versus anti-inflammatory cytokines: myth or reality. Cell Mol Biol (Noisy-le-Grand). 2001;47(4):695–702.
   PubMed Web of Science ®Google Scholar
• McCullough KC, Summerfield A. Basic concepts of immune response and defense development. ILAR J. 2005;46(3):230–240. doi:10.1093/ilar.46.3.230.
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50. doi:10.1038/cr.2009.139.
   PubMed Web of Science ®Google Scholar
• Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology. 2011;411(2):362–373. doi:10.1016/j.virol.2010.12.045.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi:10.1007/s00281-017-0629-x.
   PubMed Web of Science ®Google Scholar
• Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32. doi:10.1016/j.cytogfr.2020.05.003.
   PubMed Web of Science ®Google Scholar
• Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the. Science. 2020;369(6508):1249–1255. doi:10.1126/science.abc8665
   PubMed Web of Science ®Google Scholar
• Viswanathan T, Arya S, Chan S-H, et al. Structural basis of RNA cap modification by SARS-CoV-2. Nat Commun. 2020;11(1):3718. doi:10.1038/s41467-020-17496-8.
   PubMed Web of Science ®Google Scholar
• Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182(3):685–712.e19. doi:10.1016/j.cell.2020.06.034.
   PubMed Web of Science ®Google Scholar
• Klann K, Bojkova D, Tascher G, Ciesek S, Muench C, Cinatl J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol Cell. 2020;80(1):164–174.e4. doi:10.1016/j.molcel.2020.08.006.
   Google Scholar
• Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. doi:10.1016/j.antiviral.2020.104742.
   PubMed Web of Science ®Google Scholar
• Anand P, Puranik A, Aravamudan M, Venkatakrishnan AJ, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife. 2020;9:e58603. doi:10.7554/eLife.58603
   PubMed Web of Science ®Google Scholar
• Wynne BM, Zou L, Linck V, Hoover RS, Ma HP, Eaton DC. Regulation of lung epithelial sodium channels by cytokines and chemokines. Front Immunol. 2017;8:766 doi:10.3389/fimmu.2017.00766.
   PubMed Web of Science ®Google Scholar
• Mutchler SM, Kleyman TR. New insights regarding epithelial Na + channel regulation and its role in the kidney, immune system and vasculature. Curr Opin Nephrol Hypertens. 2019;28(2):113–119. doi:10.1097/MNH.0000000000000479.
   PubMed Web of Science ®Google Scholar
• Xu K, Cai H, Shen Y, et al. [Management of COVID-19: the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):147–157. doi:10.3785/j.issn.1008-9292.2020.02.02.
   PubMedGoogle Scholar
• Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437–437.
   PubMed Web of Science ®Google Scholar
• Li Q, Ding X, Xia G, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study. EClinicalMedicine. 2020;23:100375. doi:10.1016/j.eclinm.2020.100375
   PubMedGoogle Scholar
• Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940–948. doi:10.1080/22221751.2020.1762515.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - J. Am. Med. Assoc. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585.
   PubMed Web of Science ®Google Scholar
• Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals highlights d SARS-CoV-2-specific antibodies are detected in COVID-19 convalescent subjects ll detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:1–7.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9.
   Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193. doi:10.1016/j.chom.2016.01.007.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi:10.1016/j.cell.2020.04.026.
   PubMed Web of Science ®Google Scholar
• Konno Y, Kimura I, Uriu K, et al. USFQ-COVID19 Consortium, Nakagawa S, Sato K. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. Cell Rep. 2020;32(12):108185. doi:10.1016/j.celrep.2020.108185.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788. doi:10.1016/j.apsb.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020. doi:10.1038/s41586-020-2601-5.
   Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e15. doi:10.1016/j.cell.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Sui Y, Berzofsky JA. Myeloid cell-mediated trained innate immunity in mucosal AIDS vaccine development. Front Immunol. 2020;11:315 doi:10.3389/fimmu.2020.00315.
   PubMed Web of Science ®Google Scholar
• Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med Hypotheses. 2020;144:110049 doi:10.1016/j.mehy.2020.110049.
   PubMed Web of Science ®Google Scholar
• Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;53(2):248–263. doi:10.1016/j.immuni.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for SARS-CoV-2. J Virol. 2020;94(13):e00510-20. doi:10.1128/JVI.00510-20.
   Web of Science ®Google Scholar
• van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663–611. doi:10.1001/jama.2020.13719
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis ciaa1150. 2020. doi:10.1093/cid/ciaa1150.
   Google Scholar
• Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369(6508):1210–1220. ). eabc6261. doi:10.1126/science.abc6261
   PubMed Web of Science ®Google Scholar
• Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469. doi:10.1038/s41586-020-2588-y.
   Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26(10):1636–1643. doi:10.1038/s41591-020-1051-9.
   Web of Science ®Google Scholar
• Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 2020;5(50):eabd6832.
   PubMed Web of Science ®Google Scholar
• Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457(7229):557–561. doi:10.1038/nature07665.
   PubMed Web of Science ®Google Scholar
• Kumar A, Narayan R, Kumar S, Kumari C, Pareek V, Prasoon P. Expression of SARS-CoV-2 host cell entry factors in immune system components of healthy individuals and its relevance for COVID-19 immunopathology. Authorea Prepr. 2020. doi:10.22541/au.159656128.87988725.
   Google Scholar
• Chen y, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020;22020.03.27.20045427.
   Google Scholar
• Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–362. doi:10.1038/s41577-020-0331-4.
   Web of Science ®Google Scholar
• Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59–72.e15. doi:10.1016/j.cell.2020.05.032.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827 doi:10.3389/fimmu.2020.00827.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. doi:10.1128/IAI.72.8.4410-4415.2004.
   PubMed Web of Science ®Google Scholar
• Kumar A, Faiq MA, Pareek V, et al. Relevance of enriched expression of SARS-CoV-2 binding receptor ACE2 in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. bioRxiv. 2020. 2020.04.14.040204.
   Google Scholar
• Kaneko N, Kuo H-H, Boucau J, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020;183(1):143–157.e13. 010.1016/j.cell.2020.08.025
   PubMed Web of Science ®Google Scholar
• Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524–532.e4. S1074-7613(20)30327-7. doi:10.1016/j.immuni.2020.07.020
   PubMed Web of Science ®Google Scholar
• Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020;323(22):2245–2246. doi:10.1001/jama.2020.7869.
   PubMed Web of Science ®Google Scholar
• Vabret N. Antibody responses to SARS-CoV-2 short-lived. Nat Rev Immunol. 2020;20(9):519. doi:10.1038/s41577-020-0405-3.
   Google Scholar
• Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. doi:10.1038/s41591-020-0965-6.
   Web of Science ®Google Scholar
• To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis ciaa1275. 2020. doi:10.1093/cid/ciaa1275.
   Google Scholar
• Tillett R, Sevinsky J, Hartley P, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; S1473-3099(20)30764-7. doi:10.1016/S1473-3099(20)30764-7.
   Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168.e14. 10.1016/j.cell.2020.08.017
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973. doi:10.1016/j.jacc.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47. doi:10.1016/S2213-2600(20)30216-2
   PubMed Web of Science ®Google Scholar
• Kumar A, Narayan R, Kumari C, et al. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Med Hypotheses. 2020 Sep 30;145:110320. doi:10.1016/j.mehy.2020.110320.
   Google Scholar
• Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J. 2020;56(1):2001634. doi:10.1183/13993003.01634-2020.
   Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5) e01753-18. Published 2018 Oct 9. doi:10.1128/mBio.01753-18
   PubMed Web of Science ®Google Scholar
• Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020. 2020.03.29.20041962.
   Google Scholar
• Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. awaa240. 2020. doi:10.1093/brain/awaa240
   PubMed Web of Science ®Google Scholar
• Kumar A, Pareek V, Prasoon P, et al. Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients. J Neurosci Res. 2020;98(12):2376–2383. doi:10.1002/jnr.24717.
   Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020. 2020.03.14.988345.
   Google Scholar
• Chan C-M, Chu H, Wang Y, et al. Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. J Virol. 2016;90(20):9114–9127. doi:10.1128/JVI.01133-16.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Liu C, et al. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. PLoS Pathog. 2020;16(3):e1008392. doi:10.1371/journal.ppat.1008392.
   PubMed Web of Science ®Google Scholar
• Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–390. doi:10.1038/nature13848.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. doi:10.1016/j.cytogfr.2020.04.002.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393 doi:10.1016/j.clim.2020.108393.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009. doi:10.1183/13993003.01009-2020
   PubMed Web of Science ®Google Scholar
• Fingolimod in COVID-19. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04280588.
   Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;9913:1–7.
   Google Scholar
• Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020;127:104380 doi:10.1016/j.jcv.2020.104380.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407–1409.
   PubMed Web of Science ®Google Scholar
• Seif F, Aazami H, Khoshmirsafa M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020;181(6):467–475. doi:10.1159/000508247.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951. doi:10.1001/jama.2020.15543
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2022483.
   Web of Science ®Google Scholar
• Keech C, Albert G, Reed P, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Sep 2:NEJMoa2026920. doi:10.1056/NEJMoa2026920.
   Google Scholar
• Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023. doi:10.3332/ecancer.2020.1023.
   PubMed Web of Science ®Google Scholar
• Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2021436.
   Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, and, al., et. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Cohen J. Large trial yields strongest evidence yet that antiviral drug can help COVID-19 patients. Science. 2020. doi:10.1126/science.abc5422
   Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–277. ).
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-2 month experience. medRxiv. 2020. 2020.08.12.20169359.
   Google Scholar
• Honore PM, Hoste E, Molnár Z, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care. 2019;9(1):56 doi:10.1186/s13613-019-0530-y.
   PubMedGoogle Scholar
• Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv. 2020. 2020.05.13.092619.
   Google Scholar
• Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130:140200. doi:10.1172/JCI140200.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E006. doi:10.3760/cma.j.issn.0253-2727.2020.0006.
   PubMedGoogle Scholar
• Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710 doi:10.1371/journal.pone.0023710.
   PubMed Web of Science ®Google Scholar
• Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol. 2014;88(22):13221–13230. doi:10.1128/JVI.02078-14.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571–587. doi:10.1161/CIRCRESAHA.120.317447.
   PubMed Web of Science ®Google Scholar
• Castardeli C, Sartório CL, Pimentel EB, Forechi L, Mill JG. The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats. Biomed. Pharmacother. 2018;107:212–218.
   PubMed Web of Science ®Google Scholar
• Jung F, Krüger-Genge A, Franke RP, Hufert F, Küpper J-H. COVID-19 and the endothelium. Clin Hemorheol Microcirc. 2020;75(1):7–11. doi:10.3233/CH-209007.
   PubMed Web of Science ®Google Scholar